A Phase 2 interventional study of Metformin in Adenocarcinoma of the Endometrium, sponsored by University of Arkansas. Completed at 1 site in United States. Open to female participants aged 45 Years to 65 Years. Per ClinicalTrials.gov, last updated 2017-10-25.
Sponsored by University of Arkansas · Phase 2, Interventional, and Treatment
The purpose of this research is to determine the effects of Metformin, a well tolerated drug widely prescribed for treatment of Type 2 Diabetes Mellitus, on endometrium cancer patients.
2,004 studies on the registry are indexed under Adenocarcinoma; 374 are open to participants now.
This study's enrollment of 10 is below the median of 45 across 1,553 interventional studies indexed under Adenocarcinoma.
Browse Adenocarcinoma studies →University of Arkansas is the lead sponsor of 391 studies on the registry; 39 are open to participants now.
Of its 37 completed or terminated interventional studies of FDA-regulated products, 34 (92%) have results posted.
Counted across the registry records on this site, refreshed daily.
History of adequate renal, liver, and bone marrow function:
Exclusion Criteria:
oral metformin at 500 mg twice a day for 14-21 days followed by surgery
Drug: Metformin
IHC-based Tissue Markers of Proliferation
Time frame: 1 year
Participants were recruited from the UAMS Gynecologic Oncology Clinic between August 2013 and July 2016.
| Milestone | Group 1 - Metformin | Group 2 - No Treatment |
|---|---|---|
| Started | 6 | 4 |
| Completed | 6 | 4 |
| Not completed | 0 | 0 |
No measurements were reported for this outcome.
Collected over 3 months. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| Group 1 - Metformin | 0/6 (0%) | 0/6 (0%) | 1/6 (16.7%) |
| Group 2 - No Treatment | 0/4 (0%) | 0/4 (0%) | 0/4 (0%) |
| Event | Group 1 - Metformin | Group 2 - No Treatment |
|---|---|---|
| dysuriaRenal and urinary disorders | 1/6 | 0/4 |
| Age, Categorical(Participants) | Group 1 - Metformin | Group 2 - No Treatment | Total |
|---|---|---|---|
| <=18 years | 0 | 0 | 0 |
| Between 18 and 65 years | 4 | 4 | 8 |
| >=65 years | 2 | 0 | 2 |
| Age, Continuous(years) | Group 1 - Metformin | Group 2 - No Treatment | Total |
|---|---|---|---|
| Mean | 60.6 (42 to 72) | 61 (58 to 63) | 60.8 (42 to 72) |
| Sex: Female, Male(Participants) | Group 1 - Metformin | Group 2 - No Treatment | Total |
|---|---|---|---|
| Female | 6 | 4 | 10 |
| Male | 0 | 0 | 0 |
| Race (NIH/OMB)(Participants) | Group 1 - Metformin | Group 2 - No Treatment | Total |
|---|---|---|---|
| American Indian or Alaska Native | 0 | 0 | 0 |
| Asian | 0 | 0 | 0 |
| Native Hawaiian or Other Pacific Islander | 0 | 0 | 0 |
| Black or African American | 1 | 0 | 1 |
| White | 5 | 3 | 8 |
| More than one race | 0 | 0 | 0 |
| Unknown or Not Reported | 0 | 1 | 1 |
| Region of Enrollment(Participants) | Group 1 - Metformin | Group 2 - No Treatment | Total |
|---|---|---|---|
| United States | 6 | 4 | 10 |
Documents are hosted by the registry — open the source record to download them.
This study is completed, as verified in Sep 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
University of Arkansas